About Cypress Bioscience
Cypress Bioscience is a Healthcare company based in San Diego (United States) founded in 1981, and was acquired by Royalty Pharma in December 2010. Drugs for patients suffering from a variety of disorders of the central nervous system. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its legal entity is CYPRESS BIOSCIENCE, INC. Its competitors include Sana Biotechnology, PureTech Health and AskBio; 3 of its 3 listed competitors have raised funding.
Company details
Cypress discovers and develops drugs for patients suffering from a variety of disorders of the central nervous system. The company FDA approved products includes Prosorba, a medical device for rheumatoid arthritis; and Savella (milnacipran HCl) for fibromyalgia. Its drug pipeline includes CYP-1020 for cognitive impairment in schizophrenia, Staccato nicotine for smoking cessation and intranasal carbetocin for autism. In Dec 2010, the company was acquired by the hedge fund Ramius and drug company Royalty Pharma.
- Headquarters San Diego, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website cypressbio.com
- Social LinkedIn
- Acquired by Royalty Pharma (Dec 2010)
- Legal Name Cypress Bioscience, Inc.
- InvestorsRoyalty Pharma
& 1 more
- Acquired byRoyalty Pharma
(Dec 2010)
Investors in Cypress Bioscience
Cypress Bioscience has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Royalty Pharma and TD Securities.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made in marketed and late-stage biopharmaceutical companies. | 1996 | royaltypharma.com | New York, United States | |
Corporate finance advisory, mergers, acquisitions, and investment services are provided. | 1918 | cowen.com | New York, United States |
Investor details for Cypress Bioscience
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Cypress Bioscience
2 dated milestones of Cypress Bioscience across 29 years, from founding to its latest funding, stage changes and deals.
- Founded Cypress Bioscience is founded.
- Exit Acquired by Royalty Pharma.
Competitors of Cypress Bioscience
Cypress Bioscience has 3 listed competitors in our database, 3 of them funded. They include Sana Biotechnology, PureTech Health and AskBio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. | |
| askbio.com | 2001 | Durham, United States | $235M | Gene and protein therapies are developed for treating various diseases. |
Detailed competitors of Cypress Bioscience
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Cypress Bioscience (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cypress Bioscience
Cypress Bioscience was founded in 1981.
Cypress Bioscience is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Cypress discovers and develops drugs for patients suffering from a variety of disorders of the central nervous system. The company FDA approved products includes Prosorba, a medical device for rheumatoid arthritis; and Savella (milnacipran HCl) for fibromyalgia. Its drug pipeline includes CYP-1020 for cognitive impairment in schizophrenia, Staccato nicotine for smoking cessation and intranasal carbetocin for autism. In Dec 2010, the company was acquired by the hedge fund Ramius and drug company Royalty Pharma.
Cypress Bioscience's top competitors include Sana Biotechnology, PureTech Health and AskBio.
Cypress Bioscience has 2 investors. Key investors include Royalty Pharma, and TD Securities.
Cypress Bioscience operates through Cypress Bioscience, Inc..
Yes. Cypress Bioscience was acquired by Royalty Pharma in December 2010.